Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simplifying antiretroviral therapy.

Michael L Tapper1, Charles Flexner, Joseph J Eron

  • 1New York University School of Medicine, New York, USA.

The AIDS Reader
|July 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The High Cost of Inexpensive Medicines.

Journal of clinical pharmacology·2026
Same author

Author Correction: Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa.

Nature communications·2026
Same author

Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access.

Clinical pharmacology and therapeutics·2026
Same author

Subscription-Based Pricing for Lenacapavir-Learning From Hepatitis C and Cabotegravir.

JAMA·2026
Same author

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study.

The lancet. HIV·2025
Same author

The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases.

Annual review of pharmacology and toxicology·2025
Same journal

Effect of antiretroviral resistance on response in treatment-experienced patients.

The AIDS reader·2009
Same journal

Maximizing treatment outcome: key considerations for antiretroviral-experienced patients.

The AIDS reader·2009
Same journal

Utilizing a new class of antiretrovirals: role of fusion inhibitors in HIV disease management.

The AIDS reader·2009
Same journal

Economic crisis threatens AIDS fight.

The AIDS reader·2009
Same journal

Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?

The AIDS reader·2009
Same journal

Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.

The AIDS reader·2009
See all related articles

Highly Active Antiretroviral Therapy (HAART) simplification is key for HIV treatment adherence. New once-daily pill regimens improve patient compliance and treatment outcomes.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • HIV/AIDS Management

Background:

  • Highly Active Antiretroviral Therapy (HAART) offers significant benefits but demands strict patient adherence.
  • Early HAART regimens involved multiple daily doses and meal restrictions, posing adherence challenges.
  • Current regimens for treatment-naive HIV patients often involve once- or twice-daily dosing, still presenting scheduling difficulties.

Purpose of the Study:

  • To review the advancements in simplifying antiretroviral therapy for HIV-positive patients.
  • To discuss the emergence and evaluation of fully once-daily antiretroviral regimens.
  • To highlight factors influencing the selection of drugs for once-daily HAART.

Main Methods:

  • Review of current antiretroviral therapy (ART) regimens for HIV.

Related Experiment Videos

  • Analysis of clinical trial data for simplified, once-daily HAART combinations.
  • Discussion of pharmacokinetic, resistance, safety, and efficacy considerations for once-daily ART.

    • Main Results:

    • The development of once-daily antiretroviral agents has eased adherence burdens compared to early HAART.
    • Fully once-daily regimens represent the latest advancement in simplifying HIV treatment schedules.
    • Initial clinical trials of simplified, once-daily regimens in treatment-naive patients show promising results.

    Conclusions:

    • Simplified, once-daily HAART regimens are a promising strategy for improving adherence and outcomes in HIV management.
    • Further clinical studies are needed to establish the optimal role and timing of these simplified regimens.
    • Careful consideration of drug properties is essential when selecting components for once-daily HIV therapy.